Executive Summary

The Federal Department of the Interior opened a consultation on 19 February 2026 regarding the implementation of Cost Containment Package 2 in the pharmaceutical sector. The planned regulatory adjustments to the Health Insurance Ordinance (KVV) and Health Care Services Ordinance (KLV) are intended to slow cost development in mandatory health insurance. The consultation period runs until 26 May 2026 and affects central regulatory instruments such as cost impact models, pricing models, and vaccine reimbursement.

Persons

  • Federal Department of the Interior (lead authority)

Topics

  • Health insurance law
  • Pharmaceutical regulation
  • Cost containment in healthcare
  • Pharmaceutical price-setting

Clarus Lead

The Swiss Federal Council is implementing a legislative package to control costs in mandatory health insurance. The Federal Chambers had already adopted the measures on 21 March 2025; now concrete regulatory implementation follows through ordinance adjustments. For stakeholders – insurers, pharmaceutical industry, healthcare providers – a three-month consultation period begins for submissions.

The adjustments modernize pharmaceutical price-setting and implement new reimbursement models that are to take effect upon approval.

Detailed Summary

Cost Containment Package 2 is based on an expert report from 2017 and aims to reduce cost development in mandatory health insurance (OKP) to a medically justified level. The consultation now opened concerns concrete implementation in the pharmaceutical sector – a core cost driver of the Swiss healthcare system.

The ordinance package comprises five central measures: Cost impact models are intended to set economic incentives, pricing models to increase transparency, reimbursement from day 0 (approval date) to regulate availability of new medicines, a differentiated HBE assessment (Efficacy, Appropriateness, Efficiency) to refine evaluation, and clarification of responsibilities for vaccine reimbursement through extra-parliamentary commissions. Additionally, targeted modernizations of price-setting will be undertaken.

The consultation runs from 18 February to 26 May 2026 and is directed at cantons, associations, insurers, and other stakeholder groups. Feedback will be incorporated into final ordinance design.

Key Messages

  • Legal Basis: Implementation of Cost Containment Package 2 adopted by the Federal Council on 21 March 2025
  • Regulatory Focus: Modernization of pharmaceutical price-setting and introduction of new reimbursement models
  • Timeline: Consultation period until 26 May 2026; subsequently final ordinance adjustment
  • Objective: Limiting cost development in mandatory health insurance to medically justified levels

Critical Questions

  1. Evidence Quality: Are the cost impact and pricing models based on empirical studies on the effectiveness of similar regulations in other countries, or are they theoretical constructs without practical validation?

  2. Conflicts of Interest: Which stakeholder groups (pharmaceutical lobby, health insurers, physicians) have influenced the design of the models, and how is independence of the HBE assessment ensured?

  3. Causality and Alternatives: Is it proven that pricing models and cost impact models actually lead to cost reduction, or could quantity limitations or reference pricing systems achieve similar effects?

  4. Implementation Risks: How will delays in drug approval and availability be avoided if reimbursement only begins on day 0 – is there an incentive to postpone approvals?

  5. Vaccine Specifics: Why do vaccines require separate regulation of responsibilities, and what specific cost savings are expected here?

  6. Model Transparency: Will cost impact models be publicly documented, or will they remain confidential as trade secrets?

Source Directory

Primary Source: Consultation Opening: Federal Department of the Interior – Cost Containment Package 2 Pharmaceuticals – Published 19 February 2026

Legal Foundations:

  • Federal Health Insurance Act (KVG; SR 832.10) of 18 March 1994
  • Expert Report "Cost Containment Measures to Relieve Mandatory Health Insurance" of 24 August 2017
  • Federal Council Decision of 21 March 2025 (Cost Containment Package 2)

Verification Status: ✓ 19 February 2026

This text was created with the support of an AI model. Editorial Responsibility: clarus.news | Fact-Check: 19 February 2026